Introduction: The life cycle of infantile hemangioma (IH) and secretion of follicle-stimulating hormone (FSH) are identical. We previously have shown that IH contains the FSH receptor (FSHR). The purpose of this study was to identify which cell type(s) in IH expresses FSHR. Methods: Human proliferating IH tissues obtained during a clinically indicated surgical procedure were used. Paraffin sections and isolated cell populations (endothelial, pericyte, stem cell) were subjected to immunofluorescence for FSHR. Tissues were costained with DAPI, anti-α smooth muscle actin, or biotinylated Ulex Europaeus Agglutinin I to identify nuclei, pericytes, and endothelial cells, respectively. Whole tissue and purified single cell populations underwent polymerase chain reaction (PCR) for FSHR. Positive control specimens (ovary, sertoli cells) and negative control tissues (skin/subcutis, hepatic cells) were included. Results: Immunofluorescence of 9 IHs demonstrated that FSHR was enriched in pericytes compared with endothelial cells. Follicle-stimulating hormone receptor was expressed in 6 of 6 whole tissue IHs along with the positive control via PCR. Follicle-stimulating hormone receptor was not present in the negative control samples. Four of 5 sets of pericytes expressed FSHR by PCR. Neither IH endothelial cells, IH stem cells, nor negative control cells exhibited FSHR by PCR. Conclusions: Because the secretion of FSH correlates with the growth pattern of IH, FSH might be involved in the disease process. Follicle-stimulating hormone receptor is enriched in the pericytes of IH, suggesting that this cell type may be involved in the pathogenesis of the tumor.
I
nfantile hemangioma (IH) is the most common neoplasm of infancy, affecting 5% of whites. 1 At approximately 2 weeks of age, the tumor appears and then enlarges (proliferating phase); 80% of its growth is completed by 5 months of age. 2 The tumor begins to regress at approximately 12 months, which is completed by 3.5 years of age (involuting phase). 3 The mechanism for the growth and involution of IH is unknown. We hypothesized that follicle-stimulating hormone (FSH) might influence the pathophysiology of this tumor because it surges after birth when IH rapidly enlarges. 4 As the proliferation of the lesion slows, FSH levels decrease. Infantile hemangioma stops proliferating at the same time that an infant ceases production of FSH. 4 Girls are 3 times as likely to develop this tumor, and infant FSH levels are 5 to 7 times higher in females. 5 Children who are low birth weight have a higher frequency of developing IH and have increased secretion of FSH. 6, 7 We previously have shown that IH tissue has the FSH receptor (FSHR) by immunohistochemistry. 8 The purpose of this study was to determine which type(s) of IH cells contains FSHR.
METHODS

Patient Specimens
After approval from the Committee on Clinical Investigation at Boston Children's Hospital, proliferating IH specimens were collected during a clinically indicated procedure. Positive controls (ovary and testis) and negative controls (normal skin/subcutis and liver) were acquired from the Department of Pathology at Boston Children's Hospital.
Immunofluorescence
Immunofluorescence was used to determine the presence and location of FSHR. Formalin-fixed paraffin-embedded tissue sections were deparaffinized and immersed in a heated citric acid-based antigen unmasking solution (Vector Labs; Burlingame, Calif; H-3300). Sections were blocked using a blocking reagent (Perkin Elmer; Waltham, Mass; FP1020). Sections were stained overnight at 4°C with anti-human FSHR antibody (GeneTex; Irvine, Calif; GTX71309) alone in a 1:200 dilution or along with one of the following antibodies: anti-α smooth muscle actin (Abcam; Cambridge, Mass; ab7817) in a 1:200 dilution, anti-CD31 (Dako; Glostrup, Denmark; JC70A) in a 1:50 dilution, or antiCalponin (Abcam; Cambridge, Mass; ab700) in a 1:50 dilution. The following day, slides were incubated in biotinylated anti-rabbit, anti-mouse, or Ulex Europaeus Agglutinin I secondary antibodies (Vector Labs; Burlingame, Calif; BA-1100, BA-2000, B-1065) in a 1:200 dilution followed by Alexa Fluor 488-conjugated or 594-conjugated Streptavidin (Jackson ImmunoResearch; West Grove, Pa; 016-540-084, 016-580-084) in a 1:150 dilution. Slides were stained with DAPI (Southern Biotech; Birmingham, Ala; 0100-20) as a nuclear marker. Images were obtained using either a SPOT RT3 2Mp Slider camera (Diagnostic Instruments Inc; Sterling Heights, Mich) mounted to a Nikon Eclipse 80i microscope or a Zeiss LSM 880 with Airyscan (Zeiss; Oberkochen, Germany) confocal microscope.
Cell Isolation
Single cell suspensions were prepared from IH specimens by digesting with collagenase (Roche, Indianapolis, Ind) and isolated using magnetic microbeads for (1) VE-cadherin + endothelial cells, (2) platelet-derived growth factor B + pericytes, and (3) CD133 + stem cells. Cells were seeded on noncoated tissue culture dishes in DMEM/ 10% fetal bovine serum and analyzed for either endothelial, pericyte/ smooth muscle, or stem cell markers. 9, 10 Polymerase Chain Reaction Purified cell lines were cultured, RNA was extracted using RNeasy Mini Kit (Qiagen; Hilden, Germany; 74104), and 1μg was used to synthesize complementary DNA (cDNA) (New England Biolabs; Ipswich, Mass; E650S). Complementary DNA from cell lines and controls was processed using a Taq RED polymerase chain reaction (PCR) Master Mix (Genesee Scientific; San Diego, Calif; 42-138) with the following primer sets for FSHR and beta-actin (ACTB): FSHR Forward (5'-TCC CGA GGA ATG CCA TTG AA-3'), FSHR Reverse (5'-GGA AGG CCT CAG GGT TGA TG-3'), ACTB Forward (5'-GCC GCC AGC TCA CCA T-3'), and ACTB Reverse (5'-TCG ATG GGG TAC TTC AGG GT-3'). Polymerase chain reaction products were run on a 1% agarose gel alongside positive control (human testis cDNA) and negative control (human liver cDNA) (BioChain; Newark, Calif; C201119 and C1234149, respectively).
RESULTS
Nine proliferating IH specimens were examined (Table 1) . Immunofluorescence illustrated that FSHR was present primarily in pericytes compared with endothelial cells (Fig. 1) . Polymerase chain reaction demonstrated expression of FSHR in all IH whole tissue samples. Isolated cell population PCR experiments showed FSHR in 4 of 5 pericyte specimens. Neither endothelial (n = 3) nor stem cell (n = 3) samples exhibited FSHR by PCR (Fig. 2) .
DISCUSSION
We previously observed that FSHR is expressed in whole tissue of IH by immunohistochemistry. 8 Our current study shows that the receptor is enriched in IH pericytes, further supporting the hypothesis that the ligand for this receptor might influence the tumor's life cycle. The primary function of FSH is to promote follicular growth and spermatogenesis in the ovary and testis. 5, 11, 12 Follicle-stimulating hormone might affect IH by direct hormone interaction or indirectly through a paracrine pathway. One possibility is that FSH stimulates neovascularization in this tumor. Follicle-stimulating hormone has been implicated in the pathogenesis of cancer, which is dependent on angiogenesis and/or vasculogenesis. 13 Follicle-stimulating hormone promotes vascular endothelial growth factor (VEGF) signaling and hypoxia-inducible factor 1α in certain tissues. [13] [14] [15] Blood vessel formation requires endothelial cells to line the vessel wall and pericytes to surround them. Pericytes regulate lumen size and vessel stability by controlling endothelial cell proliferation and survival and assembly of the basement membrane. [16] [17] [18] The endothelialpericyte interaction is influenced by several molecules including angiopoietins, platelet-derived growth factor B, and VEGF-A. 19 Proliferating IH pericytes play a significant role in the tumor's growth; when IH stem cells are blocked from differentiating into pericytes in a murine model, blood vessels do not form. 20 Infantile hemangioma pericytes also have decreased contractility and low levels of angiopoietin 1, suggesting they cannot fully stabilize blood vessels. 10 Infantile hemangioma pericytes continually secrete VEGF-A, which may further affect blood vessel stimulation. Because FSH has been shown to promote VEGF signaling, [13] [14] [15] it may accentuate the proliferating effect and production of VEGF-A in IH pericytes. Interestingly, propranolol, a drug used to treat IH, significantly decreases FSH secretion 21 and has been shown to affect the contractility of IH pericytes. 22 The observation that IH pericytes express the receptor for FSH, and that the secretion of this hormone coincides with its growth, is only a correlation. Further in vitro and in vivo experiments are required to test if FSH affects the life cycle of the tumor. If an FSH pericyte interaction does influence proliferation of this tumor, targeted drug therapy for these lesions might be developed. A topical, intralesional, and/or systemic FSH antagonist could potentially prevent the growth of IH that would significantly minimize its morbidity.
